Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.

PLoS medicine - 1 Oct 2020

Zivanovic Bujak Andjelija, Weng Chen-Fang, Silva Maria João, Yeung Miriam, Lo Louisa, Ftouni Sarah, Litchfield Cassandra, Ko Yi-An, Kuykhoven Keilly, Van Geelen Courtney, Chandrashekar Sushma, Dawson Mark A, Loi Sherene, Wong Stephen Q, Dawson Sarah-Jane

Abstract excerpt

BACKGROUND: Metastatic breast cancer (mBC) is a heterogenous disease with increasing availability of targeted therapies as well as emerging genomic markers of therapeutic resistance, necessitating timely and accurate molecular characterization of disease. As a minimally invasive test, analysis of circulating tumour DNA (ctDNA) is well positioned for real-time genomic profiling to guide treatment decisions. Here,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Australia
Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Class I Phosphatidylinositol 3-Kinases

Share to Estrogen Receptor alpha

Share to Multiplex Polymerase Chain Reaction

Share to Proto-Oncogene Proteins c-akt

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 33001984
DOI: 10.1371/journal.pmed.1003363
PMCID: PMC7529214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.PMID 33001984Read ↗

Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing.Semantic proximity Read ↗

Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.Semantic proximity Read ↗

Clinical application of circulating tumor DNA in breast cancer.Semantic proximity Read ↗

Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.Semantic proximity Read ↗

Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.Semantic proximity Read ↗

Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancerSemantic proximity Read ↗

Landscape of circulating tumour DNA in metastatic breast cancer.Semantic proximity Read ↗

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.Semantic proximity Read ↗

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity Read ↗

Early-Stage Breast Cancer Detection in Breast Milk.Semantic proximity Read ↗

The dynamic range of circulating tumor DNA in metastatic breast cancer.Semantic proximity Read ↗

Development of a novel NGS methodology for ultrasensitive circulating tumour DNA detection as a tool for early-stage breast cancer diagnosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.